



**Program Announcement for the Department of Defense  
Defense Health Program**

# **Breast Cancer Research Program Clinical Research Extension Award**

Funding Opportunity Number: HT942525BCRPCREA

Pre-Application Due: June 13, 2025

Application Due: June 27, 2025

*This program announcement must be read in conjunction with the General Application Instructions, version [CD25\\_01](#).*

# Content

	<b>Before You Begin</b>	<b>3</b>
①	<b>Basic Information</b> Contains a <u>summary of the funding opportunity</u> , <u>funding details</u> , and <u>submission/review dates</u>	<b>4</b>
②	<b>Eligibility</b> Details the factors that determine <u>applicant organization</u> and <u>Principal Investigator</u> eligibility	<b>5</b>
③	<b>Program Description</b> Describes the <u>program mission</u> and <u>intent of the Clinical Research Extension Award</u> , provides <u>key award information</u> and <u>considerations</u> , and outlines <u>funding restrictions</u>	<b>6</b>
④	<b>Application Contents</b> Introduces the two-step <u>application process</u> and provides instructions for preparing a <u>pre-application</u> and <u>full application</u>	<b>10</b>
⑤	<b>Submission Requirements</b> Provides <u>locations for application packages</u> , instructions for submitting <u>pre-applications</u> and <u>full applications</u> , and describes <u>application verification</u>	<b>19</b>
⑥	<b>Application Review Information</b> Outlines the processes associated with application <u>compliance review</u> , <u>pre-application</u> and <u>full application</u> selection/notification, and <u>risk assessment</u> . Also details the complete review criteria for <u>pre-application screening</u> and both tiers of the CDMRP's application review process, <u>Peer Review</u> and <u>Programmatic Review</u>	<b>22</b>
⑦	<b>Federal Award Notices</b> Outlines what a successful applicant can expect to receive <u>if recommended for funding</u>	<b>27</b>
⑧	<b>Post-Award Requirements</b> References <u>policy requirements</u> for funded research, outlines <u>reporting requirements</u> , and restrictions related to <u>Principal Investigator changes</u> or <u>institutional award transfers</u>	<b>28</b>
⑨	<b>Other Information</b> Outlines criteria for administrative actions including application <u>rejection</u> , <u>modification</u> , <u>withdrawal</u> and <u>withhold</u>	<b>30</b>
	<b>Appendix 1</b> Includes a checklist for all full application components to facilitate application submission	<b>32</b>
	<b>Appendix 2</b> Acronym List	<b>33</b>

## Before You Begin

- **Active SAM.gov, eBRAP.org, and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read the funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of the funding opportunity and that all parties meet eligibility requirements.

## Who to Contact for Support

### eBRAP Help Desk

301-682-5507

[help@eBRAP.org](mailto:help@eBRAP.org)

*Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.*

### Grants.gov Contact Center

800-518-4726

International: 1-606-545-5035

[support@grants.gov](mailto:support@grants.gov)

*Questions regarding Grants.gov registration and Workspace.*

This document uses internal links; you can go back to where you were by pressing Alt + left arrow key (Windows) or command + left arrow key (Macintosh) on your keyboard.

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

# 1. Basic Information About the Funding Opportunity

**Summary:** The fiscal year 2025 (FY25) Breast Cancer Research Program (BCRP) Clinical Research Extension Award aims to extend or expand the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. Applications must address at least one of the FY25 BCRP overarching challenges, unless adequate justification for exception is provided.

### Distinctive Features:

- The research team must include two or more breast cancer consumer advocates.
- **This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI.** For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, applications may be withdrawn if both the initiating and partnering applications are not submitted by the full application deadline or if the initiating or partnering application is administratively withdrawn.

**Funding Details:** The Congressionally Directed Medical Research Programs (CDMRP) expects to allot approximately \$23.8 million (M) to fund approximately three Clinical Research Extension Award applications with total cost caps of \$7M for applications with a single PI or \$8.4M if applying under the PPIO. The maximum period of performance is four years. It is anticipated that awards made from this fiscal year 2025 (FY25) funding opportunity will be funded with FY25 funds, which will expire for use on September 30, 2031. Awards supported with FY25 funds will be made no later than September 30, 2026.

### Submission and Review Dates and Times

- **Pre-Application (Letter of Intent) Submission Deadline:** 5:00 p.m. Eastern Time (ET), June 13, 2025
- **Application Submission Deadline:** 11:59 p.m. ET, June 27, 2025
- **End of Application Verification Period:** 5:00 p.m. ET, July 2, 2025
- **Peer Review:** September 2025
- **Programmatic Review:** November 2025

**Announcement Type:** Modified

**Funding Opportunity Number:** HT942525BCRPREA

**Assistance Listing Number:** 12.420

## Section Shortcuts

Basic Information | [Eligibility](#) | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

## 2. Eligibility Information

### 2.1. Eligible Applicants

#### 2.1.1. Organization

Extramural and intramural organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities.***

**Extramural Organization:** An eligible non-Department of Defense (DOD) organization. Examples of extramural organizations include academic institutions, biotechnology companies, foundations, federal government organizations other than the DOD (i.e., intragovernmental organizations), and research institutes.

**Intramural DOD Organization:** Refers specifically to DOD organizations including DOD laboratories, DOD military treatment facilities, and/or DOD activities embedded within a civilian medical center.

#### 2.1.2. Principal Investigator

Independent investigators at all academic levels (or equivalent) are eligible to be named as a PI, Initiating PI, or Partnering PI on an application.

***There are no limits on the number of applications for which an investigator may be named as a PI, Initiating PI, or Partnering PI.*** However, investigators are discouraged from being named on multiple FY25 BCRP Clinical Research Extension Award applications unless they are clearly addressing distinct research questions.

Individuals affiliated with an eligible organization are eligible to be named as PI regardless of ethnicity, nationality, or citizenship status.

### 2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

### 2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the General Application Instructions, Appendix 1, for additional recipient qualification requirements.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 3. Program Description

The U.S. Army Medical Research Acquisition Activity (USAMRAA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP at the U.S. Army Medical Research and Development Command (USAMRDC) is the program office managing this FY25 funding opportunity as part of the BCRP. Congress initiated the BCRP in FY92 to support innovative, high-impact research, with a mission of ending breast cancer for Service Members and their Families, Veterans, and the general public. Appropriations for the BCRP from FY92 through FY24 totaled \$4.39 billion. The FY25 appropriation is \$130M.

The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.

The BCRP has prepared a brief overview, [The Breast Cancer Landscape](#), that describes what is currently known about the most pertinent topics that are consistent with the BCRP's mission of ending breast cancer. Considering the current breast cancer landscape and the program's mission, the BCRP seeks to invest in research that addresses the following overarching challenges:

- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility.
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth; determine how to stop it
- Identify why some breast cancers become metastatic
- Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
- Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
- Eliminate the mortality associated with metastatic breast cancer

#### 3.1. Intent of the Clinical Research Extension Award

The FY25 BCRP Clinical Research Extension Award aims to extend or expand the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical research by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. Patients' contributions of tissue, serum, and other biologic specimens and their data are invaluable to saving lives. The BCRP has created this award mechanism to help ensure that science values those contributions with research that maximizes their impact.

Although not all inclusive, the scope of research that this award mechanism supports includes projects entailing a deeper molecular analysis of clinical samples, initiation of new correlative studies, biomarker validation, or continuing clinical follow-up of patients enrolled in an

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

open/ongoing or completed clinical trial. The proposed research may be hypothesis-testing or -generating or may be designed to generate clinically annotated and molecularly characterized experimental platforms, including patient-derived models or tissue arrays. Innovation is not a criterion for this award mechanism. ***Projects proposing to conduct clinical trials will not be supported.***

### 3.1.1. Key Elements for the Clinical Research Extension Award

**Impact:** Research supported by the FY25 BCRP Clinical Research Extension Award will have the potential to extend or affect the impact of the previously funded clinical trial or study, or will result in new impact and accelerate progress toward ending breast cancer.

**Overarching Challenges:** Considering the current breast cancer landscape and the BCRP's mission, all applications must address at least one of the above [overarching challenges](#) unless adequate justification for exception is provided.<sup>1</sup> Applicants are strongly urged to read and consider [The Breast Cancer Landscape](#) before preparing their applications.

**Feasibility:** Preliminary data to support the scientific rationale and feasibility of the research approaches are required. The applicant must demonstrate availability of, and access to, the necessary resources and/or populations to accomplish the proposed research.

**Data Evaluation and Sharing:** Proposed research should be based on a study sample size that will ensure the results support valid conclusions or will generate a meaningful hypothesis. It is the applicant's responsibility to provide sufficient evidence that the sample size is appropriate to meet the study's objective and to outline the statistical methods and considerations they will employ in their data analysis. The applicant must outline a data sharing plan for the scientific community to have access to the experimental platforms and molecular and other data generated from the proposed research.

**Personnel:** Applications must include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.

**Consumer Advocates:** The research team must include two or more breast cancer consumer advocates, and it is the applicant's responsibility to outline the advocates' role in the design and execution of the study. As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in a breast cancer advocacy organization. Their role should be independent of their employment, and they cannot be employees of any organizations participating in the application. The consumer advocates should have a high level of knowledge of current breast cancer issues and the appropriate background and/or training in breast cancer research to contribute to the project. Their role should be focused on providing objective input throughout the research effort and its potential impact for individuals with, or at risk for, breast cancer.

**Partnering PI Option:** The FY25 BCRP Clinical Research Extension Award encourages applications that include meaningful and productive partnerships between investigators. The PPIO accommodates two PIs. One PI will be the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be the Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each

---

<sup>1</sup> Alternatively, with adequate justification, applications may identify and address another overarching challenge related to The Breast Cancer Landscape. Justification must be provided in the application.

## Section Shortcuts

Basic Information | Eligibility | [Program Description](#) | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

PI must bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. The application should balance funding between both PIs unless appropriately justified. The PPIO encourages, but does not require, new partnerships. The application should describe how the PIs' unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the proposed project, and why the work should be done together rather than through separate efforts. **To meet the intent of the Partnering PI Option, the BCRP discourages applicants from being named as a Partnering PI on multiple Clinical Research Extension Award applications unless they are clearly unique, meaningful partnerships addressing distinct research questions.** If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to [Section 5.3, Submission Instructions](#).

### 3.1.2. Other Important Considerations for the Clinical Research Extension Award

**Clinical research** encompasses research with human data, human specimens, and/or interaction with human subjects that may or may not be considered a clinical trial. For the purpose of this funding opportunity, research involving human data, human anatomical substances, and/or interaction with human subjects, including extended or expanded clinical follow-up of patients, is permitted; **however, this award cannot be used to conduct clinical trials.**

**A clinical trial is defined** in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. An **intervention** includes both physical procedures by which information or biospecimens are gathered and manipulations of the subject or the subject's environment that are performed for research purposes.

**Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.**

**The proposed research must be relevant to Service Members, Veterans, military beneficiaries, and/or the American public.** Applications from investigators within the DOD and applications involving multidisciplinary collaborations among academia, industry, the DOD, the U.S. Department of Veterans Affairs (VA), and other federal government agencies are highly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the collaborators bring to the research effort, ultimately advancing research that is of significance to Service Members, Veterans, and/or their Families.

### 3.2. CDMRP-wide Encouragements

The following encouragements are broadly applicable across many CDMRP programs, including the BCRP. Investigators are encouraged to consider addressing these areas in their applications if doing so is appropriate for their line of research and meets the intent of this funding opportunity.

A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the

## Section Shortcuts

[Basic Information](#) | [Eligibility](#) | [Program Description](#) | [Application Contents and Format](#) | [Submission Requirements](#)  
[Application Review Information](#) | [Federal Award Notices](#) | [Post-Award Requirements](#) | [Other Information](#)

lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the [recommendations](#) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY25 BCRP priorities.

Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.

### 3.3. Funding Instrument

The funding instrument for awards made under the program announcement will be grants (31 USC 6304).

### 3.4. Funding Details

**Period of Performance:** The maximum period of performance is **four** years.

**Cost Cap:** For applications with a single PI, the application's total costs budgeted for the entire period of performance should not exceed **\$7M**. For Partnering PI Option applications, the combined total costs budgeted for the entire period of performance in the applications of the Initiating PI and the Partnering PI should not exceed **\$8.4M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

For Partnering PI Option applications, a separate award will be made to each PI's organization.

All direct and indirect cost of any subaward or contract must be included in the direct costs of the primary award.

The applicant(s) may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **four** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

**Direct Cost Restrictions:** For this award mechanism, direct costs:

May be requested for (not all-inclusive):

- Travel in support of multi-institutional collaborations.
- Research subject compensation and reimbursement for study-related out-of-pocket costs (e.g., travel, lodging, parking, costs associated with caregiving, and resources/equipment to enable participation), if applicable.
- Costs for three investigators to travel to one scientific/technical meeting per year. The intent of travel to scientific/technical meetings should be to present project information or disseminate project results from the FY25 BCRP Clinical Research Extension Award.

Must not be requested for:

- Clinical trial costs.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

# 4. Application Contents and Format

## 4.1. Application Overview

Application submission is a two-step process requiring both a **pre-application** submitted via the Electronic Biomedical Research Application Portal ([eBRAP](#)) and a **full application** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

***Intramural DOD organizations submitting a full application should follow instructions for submission through eBRAP.***

***Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.***

## 4.2. Step 1: Pre-Application Components

Pre-application submissions must include the following component.

**Letter of Intent (LOI) (one-page limit):** Provide a brief description of the research to be conducted. Include the overarching challenge(s) under which the application will be submitted.

## 4.3. Step 2: Full Application Components

Each application submission must include the completed full application package for this program announcement. See [Appendix 1](#) for a checklist of the full application components.

**Partnering PI Option:** The CDMRP requires separate full application package submissions for the Initiating PI and each Partnering PI, even if the PIs are located within the same organization. The application submission process for the Partnering PI uses an [abbreviated full application package](#).

### 4.3.1. Full Application Components for the PI or Initiating PI

(a) **SF424 Research & Related Application for Federal Assistance Form (*Grants.gov Submissions Only*):** Refer to the General Application Instructions, Section IV.B.(a), for detailed information.

**IMPORTANT: When completing the SF424 R&R, enter the eBRAP log number assigned during pre-application submission into Block 4a – Federal Identifier.**

#### (b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines listed in the General Application Instructions, Appendix 2.

- **Attachment 1: Project Narrative (18-page limit): Upload as “ProjectNarrative.pdf”.** The page limit of the Project Narrative applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs (uniform resource locators) that provide additional information that expands the Project Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the application.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

Describe the proposed project in detail using the outline below.

- **Background:** Present the ideas and reasoning behind the proposed research and identify the [FY25 BCRP Overarching Challenge](#) that the study will address. Provide a sound scientific rationale to support the proposed project and its feasibility as established through the demonstration of logical reasoning and a critical review and analysis of published literature; include relevant literature citations. Describe how the proposed work will extend or expand the data collection, follow-up, and/or analysis of a breast cancer trial or other clinical study. **Include preliminary data to support the scientific rationale and feasibility of the research approaches.**
- **Hypothesis or Objective:** State the hypothesis to be tested or generated or the objective to be reached.
- **Specific Aims:** Concisely explain the project’s specific aims to be funded by this application.
- **Research Strategy and Feasibility:**
  - Provide a detailed description of the database, specimens, other resource, or clinical trial(s) or study the proposed project will extend or expand. Include, if relevant, the National Clinical Trial (NCT) number, funding source, design, number of patients enrolled, relevant results to date, and the location and quantity of data/specimens that are available from the trial(s) or study.
  - Describe the experimental design, methods, and analyses. Provide a detailed description of planned methods to address the hypothesis/objective of the extension research.
  - The proposed studies are expected to generate or test a hypothesis. Hence, it is essential that the application outline in detail the data analysis plan, statistical methods, and considerations that will be employed to analyze the data and draw meaningful conclusions or generate hypotheses. Include sample size projections and an appropriate power analysis, **if applicable**, to demonstrate that the sample size is appropriate to meet the objective.
  - Address potential problem areas and present alternative methods and approaches.
  - Describe the availability of and access to the appropriate resources, data, cohort(s), and/or human samples, and provide appropriate letters of support in [Attachment 2: Supporting Documentation](#). See [Attachment 9: Inclusion of Women and Minorities](#) for the required strategy for the inclusion of women and minorities appropriate to the objectives of the study. **This award cannot be used to conduct clinical trials.**
  - Briefly describe how data will be reported and shared. **Provide details of data and resource sharing in [Attachment 10: Data and Research Resources Sharing Plan](#).**
- **Attachment 2: Supporting Documentation: Combine and upload as a single file named “Support.pdf”.** Start each document on a new page. The Supporting Documentation attachment should not include additional information such as figures, tables, graphs, photographs, diagrams, chemical structures, or drawings. These items should be included in the Project Narrative.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

***There are no page limits for any of these components unless otherwise noted. Include only those components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.***

- **References Cited:** List the references cited (including URLs, if available) in the Project Narrative using a standard reference format.
- **List of Abbreviations, Acronyms, and Symbols:** Provide a list of abbreviations, acronyms, and symbols.
- **Facilities, Existing Equipment, and Other Resources:** Describe the facilities and equipment available for performance of the proposed project and any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference should be made to the original or present government award under which the facilities or equipment items are now accountable. There is no form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support:** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should confirm that the PI(s) meet [eligibility criteria](#). If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOD collaborator(s) and/or access to military populations, databases, or DOD resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or individual designated by the VA Facility Director(s), confirming access to VA patients, resources, and/or VA research space.
- **Consumer Advocate Letters of Commitment:** Provide a letter signed by each consumer advocate confirming their commitment to participate in the proposed project.
- **Intellectual and Material Property Plan (if applicable):** Provide a plan for resolving intellectual and material property issues among participating organizations.
- **Sex as a Biological Variable Strategy (two-page limit is recommended):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data, or other relevant considerations (e.g., use of a pre-existing cohort for research extending or expanding an existing clinical trial or study). Refer to the [CDMRP Directive on Sex as a Biological Variable in Research](#) for additional information.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Attachment 3: Technical Abstract (one-page limit): Upload as “TechAbs.pdf”.** The technical abstract is used by all reviewers. **Abstracts of all funded research projects will be posted publicly.** Use only characters available on a standard QWERTY keyboard; spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed.

Technical abstracts should be written using the outline below. Clarity and completeness within the space limits are highly important.

- **Background:** Present the scientific rationale behind the proposed research project.
  - **Overarching Challenge(s):** State the overarching challenge(s) addressed by the proposed research.
  - **Hypothesis/Objective:** State the hypothesis to be tested or generated, or the objective to be reached. Provide supporting evidence or rationale for the hypothesis/objective.
  - **Specific Aims:** State the specific aims of the study.
  - **Study Design:** Briefly describe the study design.
  - **Impact:** Briefly describe how the project will extend or expand the impact of the previously funded clinical trial or study or will result in new impact. Describe how the proposed project will have an impact on at least one of the overarching challenges and accelerate progress toward ending breast cancer.
  - **Relevance to Military Health:** Briefly describe how the proposed research is relevant to Service Members, Veterans, and their Families.
- **Attachment 4: Lay Abstract (one-page limit): Upload as “LayAbs.pdf”.** The lay abstract is used by all reviewers and addresses issues of particular interest to the affected community. **Abstracts of all funded research projects will be posted publicly.** Use only characters available on a standard QWERTY keyboard; spell out all Greek letters, other non-English letters, and symbols. Graphics are not allowed. **Do not duplicate the technical abstract.**

Lay abstracts should address the points outlined below ***in a manner that will be readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms, and abbreviations.

- Clearly describe the rationale, objective, and aims of the application.
- Describe the ultimate applicability and impact of the research.
  - Which overarching challenge(s) does the research address?
  - What types of patients or at-risk individuals will it help and how will it help them?
  - What are the potential clinical applications, benefits, and risks?
  - What is the projected time it may take to achieve a patient-related outcome?
  - What is the likely impact of this study on the BCRP’s mission of ending breast cancer?
  - How is the proposed research relevant to Service Members, Veterans, and their Families?

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Attachment 5: Statement of Work (three-page limit): Upload as “SOW.pdf”.** Refer to eBRAP for the ["Suggested SOW Format"](#).

For the FY25 BCRP Clinical Research Extension Award, refer to either the ["Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work"](#) or ["Example: Assembling a Generic Statement of Work"](#), whichever example is most appropriate for the proposed effort, for guidance on preparing the SOW.

The SOW should indicate a feasible plan and timeline to conduct the research. The SOW must include specific research milestones to be accomplished by the end of each year in the period of performance.

***Partnering PI Option: Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Initiating PI and the Partnering PI should be clearly noted for each task.***

- **Attachment 6: Impact Statement (300 words or less is recommended; one-page limit): Upload as “Impact.pdf”.**

***This statement should be written with a broad audience in mind, including readers without a background in science or medicine. DO NOT restate the research strategy as part of the Impact Statement.***

- Articulate concisely how the proposed research will extend or expand the impact of the previously funded clinical trial or study or will result in new impact.
- Explain how the proposed research will have an impact on at least one of the overarching challenges and accelerate progress toward ending breast cancer.
- Identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research. Justify how these individuals would benefit from the project.
- Explain briefly how the proposed research is relevant to Service Members, Veterans, and their Families.

- **Attachment 7: Partnership Statement (one-page limit): Upload as “Partnership.pdf”.** (*Attachment 7 is only applicable and required for applications submitted under the Partnering PI Option.*) Describe the partnership and combined expertise of the Initiating and Partnering PI that are critical for the research strategy and completion of the proposed work. Explain how the partnership will better address the research question and why the work should be done together rather than through separate individual efforts. Explain how both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. Explain the plan to balance funding between both PIs, or otherwise provide appropriate justification.

- **Attachment 8: Research Team Statement (one-page limit): Upload as “Team.pdf”.** Describe how the PI’s and research team’s combined backgrounds and breast cancer-related expertise will contribute to accomplishing the research goals. Provide the names of at least two consumer advocates and their affiliation with a breast cancer advocacy organization(s). Describe how the consumer advocates’ knowledge of current breast cancer issues and how their background and/or training in breast cancer research will contribute to the proposed research. Explain how the consumer advocates will be integrated into the design and execution of the study.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Attachment 9: Inclusion of Women and Minorities (four-page limit): Upload as “Inclusion.pdf”.** Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial, and ethnic group, and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the [Public Health Service \(PHS\) Inclusion Enrollment Report](#), a three-page fillable PDF form that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race, and ethnicity. For research extending or expanding an existing clinical trial or study to conduct additional patient follow-up, sample collection, or analyses, use of the patients enrolled in that trial or study is expected and the study potentially may not include diverse populations. Explain how the pre-existing cohort is appropriate for the study objectives. ***Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement and may submit N/A for this statement.***
  - **Attachment 10: Data and Research Resources Sharing Plan (two-page limit): Upload as “Sharing.pdf”.** Describe the type of data or research resources to be made publicly available as a result of the proposed work. Describe how data and resources generated during the performance of the proposed research project will be shared with the research community and other affected communities. This includes cases where pre-existing data or resources will be utilized and/or modified during the course of the proposed project. Specifically describe a plan to make experimental platforms, tissue samples, and other data and resources developed as a part of the proposed research project available to the scientific community. If there are limitations associated with a pre-existing agreement for the original data or research resources that preclude subsequent sharing, provide an explanation and justification. Provide a milestone plan for data/results dissemination including when data and resources will be made available to other users. Refer to the CDMRP [Policy on Data & Resources Sharing](#) for more information about the CDMRP’s expectations for making data and research resources publicly available.
  - **Attachment 11: Representations (Grants.gov submissions only): Upload as “RequiredReps.pdf”.** All extramural applicants must complete and submit the [“Required Representations”](#) document that is available on eBRAP. For more information, see the General Application Instructions, Appendix 8, Section B, Representations.
  - **Attachment 12: Suggested Intragovernmental/Intramural Budget Form (if applicable): Upload as “IGBudget.pdf”.** If an [intramural DOD organization](#) will be a collaborator in the performance of the project, complete a separate budget for that organization using the [“Suggested Intragovernmental/Intramural Budget”](#) form that is available for download on eBRAP. Refer to the General Application Instructions, Section V.B.(c), for instructions and considerations.
- (c) **Research & Related Personal Data:** For detailed instructions for Grants.gov submissions, refer to the General Application Instructions, Section IV.C.(a); and for eBRAP submissions, refer to the General Application Instructions, Section V.B.(a).
- (d) **Research & Related Senior/Key Person Profile (Expanded):** Complete a Profile for each person who will contribute in a substantive, meaningful way to the scientific development or execution of the proposed research project. A biographical sketch and full description of

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

each PI and senior/key person's current/pending support information must be attached to the individual's profile in the Attach Biographical Sketch and Attach Current & Pending Support fields, respectively. ***Biographical sketches or equivalent must be submitted for the breast cancer consumer advocates.***

- **Biographical Sketch:** Upload as "**Biosketch\_LastName.pdf**".

The CDMRP staff and reviewers use biosketches to evaluate whether research teams are equipped with the expertise necessary to carry out the proposed research.

Biosketches must conform to the federal-wide Biographical Sketch Common Form. To prepare their biosketch attachments, applicants may use the instructions provided in the General Application Instructions, Section IV.C.(b), for Grants.gov submissions; or General Application Instructions, Section V.B.(b), for eBRAP submissions; or may use a pdf form created in [SciENCv](#) for the National Institutes of Health (NIH) or the U.S. National Science Foundation (NSF).

- **Current/Pending Support:** Upload as "**Support\_LastName.pdf**".

Current and pending (other) support information are used to assess the capacity or any [conflicts of commitment](#) that may impact the ability of the individual to carry out the research effort as proposed. The information also helps to assess any potential scientific and budgetary overlap/duplication with the project being proposed.

Current and pending support documentation must conform to the federal-wide format. To prepare their Current and Pending Support form, applicants may use the instructions provided in the General Application Instructions, Section IV.C.(b), for Grants.gov submissions; or General Application Instructions, Section V.B.(b), for eBRAP submissions; or may use a pdf form created in [SciENCv](#) for NIH or NSF.

- (e) **Research & Related Budget:** For detailed instructions for Grants.gov submissions, refer to the General Application Instructions, Section IV.C.(c); and for eBRAP submissions, refer to the General Application Instructions, Section V.B.(c).
  - **Budget Justification (no page limit):** For instructions for Grants.gov submissions, refer to the General Application Instructions, Section IV.C.(c), Section L; for eBRAP submissions, refer to General Application Instructions, Section V.B.(c), Budget Justification Instructions.

***Partnering PI Option: Initiating and Partnering PIs must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Initiating PI should not include budget information for Partnering PI even if they are located within the same organization. Refer to [Section 3.4, Funding Details](#), for detailed information.***

- (f) **Project/Performance Site Location(s) Form:** For detailed instructions for Grants.gov submissions, refer to the General Application Instructions, Section IV.C.(d); and for eBRAP submissions, refer to the General Application Instructions, Section V.B.(d).
- (g) **Research & Related Subaward Budget Attachment(s) Form (if applicable, Grants.gov Submissions only):** Refer to the General Application Instructions, Section IV.C.(e), for detailed information.
  - **Extramural Subaward:** Complete the Research & Related Subaward Budget Form and upload it through Grants.gov.

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

- **Intramural DOD Subaward:** Complete a separate "[Suggested Intragovernmental/Intramural Budget Form](#)" for each intramural DOD subaward. Combine them into a single document, then upload the file to Grants.gov as an attachment named "IGBudget.pdf".

### 4.3.2. Full Application Components for the Partnering PI

Refer to the equivalent attachment above for details specific to each of the following application components. See [Appendix 1](#) for a checklist of the full application components required for the Partnering PI.

- (a) **SF424 Research & Related Application for Federal Assistance Form (*Grants.gov Submissions Only*):** Refer to the General Application Instructions, Section IV.B.(a), for detailed information.

**NOTE: Enter the eBRAP log number assigned during pre-application submission into Block 4a – Federal Identifier Box**

(b) **Attachments:**

- **Attachment 5: Statement of Work (three-page limit): Upload as "SOW.pdf".** Each PI must submit an identical copy of a jointly created SOW.
  - **Attachment 11: Representations (*Grants.gov submissions only*): Upload as "RequiredReps.pdf".**
  - **Attachment 12: Suggested Intragovernmental/Intramural Budget Form: Upload as "IGBudget.pdf".**
- (c) **Research & Related Personal Data:** For detailed instructions for Grants.gov submissions, refer to the General Application Instructions, Section IV.C.(a); and for eBRAP submissions, refer to the General Application Instructions, Section V.B.(a).
- (d) **Research & Related Senior/Key Person Profile (Expanded):** Complete a Profile for each person who will contribute in a substantive, meaningful way to the scientific development or execution of the proposed research project. A biographical sketch and full description of each PI and Senior/Key Person's current/pending support information must be attached to the individual's Profile in the Attach Biographical Sketch and Attach Current & Pending Support fields, respectively. ***Biographical sketches or equivalent must be submitted for the breast cancer consumer advocates.***
- (e) **Research & Related Budget:** For detailed instructions for Grants.gov submissions, refer to the General Application Instructions, Section IV.C.(c); and for eBRAP submissions, refer to the General Application Instructions, Section V.B.(c).
- **Budget Justification (no page limit):** Upload as "BudgetJustification.pdf".
- Initiating and Partnering PI must have a separate budget and justification specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Partnering PI should not include budget information for the Initiating PI, even if they are located within the same organization. Refer to [Section 3.4, Funding Details](#), for detailed information.***
- (f) **Project/Performance Site Location(s) Form:** For detailed instructions for Grants.gov submissions, refer to the General Application Instructions, Section IV.C.(d); and for eBRAP submissions, refer to the General Application Instructions, Section V.B.(d).

## Section Shortcuts

Basic Information | Eligibility | Program Description | [Application Contents and Format](#) | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

**(g) Research & Related Subaward Budget Attachment(s) Form (if applicable, Grants.gov Submissions Only):** Refer to the General Application Instructions, Section IV.C.(e), for detailed information.

- **Extramural Subaward:** Complete the Research & Related Subaward Budget Form through Grants.gov.
- **Intramural DOD Subaward:** Complete the "[Suggested Intragovernmental/Intramural Budget Form](#)" for each intramural DOD subaward and upload as a single document titled IGBudget.pdf to Grants.gov.

### 4.4. Other Application Elements

- If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, [DoD Instruction 3200.12](#) will be requested.
- The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

# 5. Submission Requirements

## 5.1. Location of Application Package

Download the application package components for HT942525BCRPREA from [Grants.gov](#) or [eBRAP](#), depending on which submission portal will be used.


## 5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), [SAM.gov](#), and receive confirmation of an “Active” status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration. More information regarding SAM registration can be found in the General Application Instructions, Section IV.A.

## 5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions.

### *Application Submission Workflow*



## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 5.3.1. Pre-Application Submission

All pre-application components must be submitted by the PI or initiating PI through eBRAP (<https://eBRAP.org/>), including the submission of contact information for the Partnering PI if exercising the Partnering PI Option.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during [the full application submission process](#). The eBRAP log number, application title, and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify, and verify the application in eBRAP. If any changes need to be made, the applicant should contact the eBRAP Help Desk at [help@eBRAP.org](mailto:help@eBRAP.org) or 301-682-5507 prior to the application submission deadline.

**Partnering PI Option:** After the Initiating PI confirms submission of the pre-application, the Partnering PI will be notified of the pre-application submission via an email from eBRAP. ***The Partnering PI must follow the link in the notification email to associate the partnering pre-application with their eBRAP account and confirm their organization and Business Official information.*** If not previously registered, the Partnering PI must register in eBRAP.

***Partnering PIs should not initiate a new pre-application based on the same research project submitted by the Initiating PI.*** Partnering PIs are urged to associate the partnering pre-application with their eBRAP account as soon as possible. If this is not completed by the full application deadline:

- The Partnering PI will not be able to view and modify their full application during the verification period in eBRAP.
- Any intramural Partnering PI will not be able to submit their full application package components to eBRAP.

When starting the pre-application, applicants will be asked to select a “Mechanism Option”. Be sure to select the correct option appropriate to your pre-application:

Application Includes:	Select Option:
Single PI	No Option
Initiating PI and Partnering PI	Partnering PI Option

Refer to the General Application Instructions, Section III.A, for considerations and detailed instructions regarding pre-application submission.

### 5.3.2. Full Application Submission

**Grants.gov Submissions:** Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace. Refer to the General Application Instructions, Section IV, for considerations and detailed instructions regarding Grants.gov submissions.

**eBRAP Submissions:** Only intramural DOD organizations may submit full applications through eBRAP. Full applications from extramural organizations, including non-DOD federal organizations, received through eBRAP will be withdrawn. Refer to the General Application Instructions, Section V, for considerations and detailed instructions regarding eBRAP submissions.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | [Submission Requirements](#)  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

### 5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log into eBRAP to review, modify, and verify the full application submission. Verification is strongly recommended but not required. eBRAP will validate full application files against the specific program announcement requirements, and discrepancies will be noted in the “Full Application Files” tab in eBRAP. However, eBRAP does not confirm the accuracy of file content. It is the applicant’s responsibility to review all application components and ensure the proper ordering as specified in the program announcement. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline. If either the Project Narrative or the budget fails eBRAP validation or needs to be modified, an updated full application package must be submitted through the appropriate portal prior to the full application submission deadline.*** Other application components, including subaward budget(s) and subaward budget justification(s), may be changed until the end of the [application verification period](#). The full application cannot be modified once the application verification period ends.

### 5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The USAMRAA cannot make allowances/exceptions for submission problems encountered by the applicant.***

All submission dates and times are indicated in [Section 1, Basic Information](#) above.

### 5.5. Intergovernmental Review

Not applicable for this funding opportunity.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

# 6. Application Review Information

## 6.1. Application Compliance Review

***Submitting applications that propose essentially the same research project to different funding opportunities within the same program and funding cycle is prohibited and will result in administrative withdrawal of the duplicative application(s).***

While it is allowable to propose similar research projects to different programs within CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the [CDMRP's full position on research duplication](#).

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal. Refer to the General Application Instructions, Appendix 7, Section B.

Members of the FY25 BCRP Programmatic Panel should not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation, and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic Panel members **may** provide [letters](#) to confirm [PI eligibility](#) and access to laboratory space, equipment, and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). **A list of the [FY25 BCRP Programmatic Panel](#) members can be found on the CDMRP website.**

Additional restrictions and associated administrative responses are outlined in [Section 9.2, Administrative Actions](#).

## 6.2. Review Criteria

### 6.2.1. Pre-Application Screening Criteria

Pre-applications submitted to this funding opportunity are used for program planning purposes only (e.g., reviewer recruitment) and will not be screened.

### 6.2.2. Peer Review Criteria

To determine technical merit, all applications will be individually evaluated according to the following **scored criteria**, which are of equal importance:

- **Impact**

**Note:** Reviewers will evaluate how the proposed research will have an impact on the overarching challenge(s), assuming the objective/goals are realized.

- To what degree the proposed research will extend or expand the impact of the previously funded clinical trial or study or will result in new impact.
- To what degree the project will have an impact on at least one of the overarching challenges and accelerate the progress toward ending breast cancer.
- To what degree the application justifies how the identified breast cancer patients or at-risk individuals would benefit from the proposed research.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- **Research Strategy and Feasibility**

- How well the scientific rationale supports the proposed research and its feasibility, as demonstrated by logical reasoning, a critical review and analysis of the published literature, and the presentation of preliminary data.
- How well the application develops the hypothesis to be tested or generated, or the objective to be achieved, and specific aims are developed.
- Whether the application adequately describes the database, specimens, or other resource or clinical trial(s) or study that the proposed project will extend or expand. If relevant, whether the application includes the NCT number, funding source, design, number of patients enrolled, relevant results to date, and the location and quantity of data/specimens that are available from the trial(s) or study.
- How well the experimental design, methods, and analyses are developed and support completion of the specific aims.
- Whether the data analysis plan, statistical methods, and considerations for analyzing the data and drawing meaningful conclusions or generating hypotheses are appropriate for the study. Whether the sample size projections and power analysis, **if applicable**, demonstrate that the sample size is appropriate for meeting the objectives of the study.
- How well the application acknowledges potential problems and addresses alternative methods and approaches.
- How well the SOW indicates a feasible plan and timeline to conduct the research and provides clearly defined milestones to accomplish by the end of each year in the period of performance.
- Whether the application provides sufficient information to support the availability of and access to the appropriate resources, data, cohort(s), and/or human samples.
- Whether the strategy for the inclusion of women and minorities and distribution of proposed enrollment are appropriate for the proposed research (if applicable). If the proposed research will extend or expand an existing clinical trial or study, whether the application sufficiently describes how the pre-existing cohort is appropriate for the study objectives.
- Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single sex study is sufficiently strong.

- **Personnel**

- Whether the application includes an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.
- Whether two or more consumer advocates are named in the application and meet the criteria according to the program announcement.
- How well the consumer advocates' knowledge of current breast cancer issues, and how their background and/or training in breast cancer research will contribute to the proposed research.
- How well the application demonstrates integration of consumer advocates into the design and execution of the study.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- How appropriate the levels of effort are for successful conduct of the proposed work.
- **Partnership (*only applicable to Partnering PI Option applications*)**
  - How well the partnership and combined expertise of the Initiating and Partnering PIs contribute to the research strategy and completion of the proposed work.
  - To what degree the partnership will better address the research question together rather than through separate individual efforts.
  - How well the application reflects equal intellectual input by both PIs into the design of the project, and similar and appropriate levels of effort devoted to the conduct of the project.
  - Whether the proposed funding is balanced between both PIs, or is otherwise appropriately justified.
- **Data and Resources Sharing Plan**
  - To what degree plans for sharing data and resources generated during the performance of the research project with the research community and other affected communities are appropriate.
  - Whether the application specifically describes a plan to make experimental platforms, tissue samples, and other data and resources developed as a part of the proposed research projects, available to the scientific community.
  - If applicable, to what degree the application explains and justifies potential limitations associated with a pre-existing agreement for the original data or research resources that preclude subsequent sharing.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of, and access to, facilities and resources.
  - If applicable, to what degree the intellectual and material property plan is appropriate.
- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Application Presentation**
  - To what extent the writing, clarity, and presentation of the application components influence the review.

### 6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of the peer reviewers
- Relevance to the priorities of the FY25 BCRP, as evidenced by the following:

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

- Adherence to the intent of the funding opportunity
- Program portfolio composition
- Relative impact

### 6.3. Application Review and Selection Process

#### 6.3.1. Pre-Application

There is no review and selection process for pre-applications submitted to this funding opportunity. **CDMRP will NOT provide an invitation to submit a full application after pre-application submission.** Applicants are encouraged to develop pre-application and full application components concurrently and submit a full application AFTER successful submission of the pre-application.

#### 6.3.2. Full Application

All applications are evaluated by scientists, clinicians, and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are made to the Commanding General, USAMRDC. **The highest-scoring applications from the first tier of review are not automatically recommended for funding. Funding recommendations depend on various factors as described in [Section 6.2.3, Programmatic Review](#).** Additional information about the two-tier process used by the CDMRP can be found on the [CDMRP website](#).

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a [limited time period](#) based on the fiscal year of the funds.

### 6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in 2 CFR 200.1, over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in SAM.

An applicant organization may review SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics, and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum and all associated laws, all fundamental research funded by the DOD must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
[Application Review Information](#) | Federal Award Notices | Post-Award Requirements | Other Information

of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the [DOD Component Decision Matrix](#) must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | [Federal Award Notices](#) | Post-Award Requirements | Other Information

## 7. Federal Award Notices

For each full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within six weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the BCRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

***Only an appointed USAMRAA Grants Officer may obligate the government to the expenditure of funds to an extramural organization.*** No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

***Intra-DOD obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.***

Funding obligated to ***intragovernmental and intramural DOD organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD), or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOD investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award. For additional information about pre-award costs for Grants.gov submissions, refer to the General Application Instructions, Section I.D, Pre-Award Costs section; and for eBRAP submissions, refer to the General Application Instructions, Section 1.D, Pre-Award Costs section.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

# 8. Post-Award Requirements

## 8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

Refer to the General Application Instructions, Appendix 7, for general information regarding administrative requirements.

Refer to the General Application Instructions, Appendix 8, for general information regarding national policy requirements.

Refer to full text of the latest [DoD R&D Terms and Conditions](#) and the [USAMRAA Research Terms and Conditions: Addendum to the DoD R&D Terms and Conditions](#) for further information.

***If there are technical reporting requirement delinquencies for any existing CDMRP awards at the applicant organization, no new awards will be issued to the applicant organization until all delinquent reports have been submitted.***

Applications recommended for funding that involve animals, human data, human specimens, human subjects, or human cadavers must be reviewed for compliance with federal and DOD animal and/or human subjects protection requirements and approved by the USAMRDC Office of Human and Animal Research Oversight (OHARO), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), IRB, or Ethics Committee (EC) review. Refer to the General Application Instructions, Appendix 6, for additional information.

## 8.2. Reporting

Annual technical progress reports as well as a final technical progress report will be required. Annual and final technical reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Award Expiration Transition Plan: An [Award Expiration Transition Plan](#), using the template available on eBRAP, must be submitted with the final progress report.

PHS Inclusion Enrollment Reporting (***Required for research proposing clinical research***): Enrollment reporting on the basis of sex, race, and/or ethnicity will be required with each annual and final progress report. The [PHS Inclusion Enrollment Report](#) is available on eBRAP.

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant, and cooperative agreement awards with a cumulative total value greater than \$10M are required to provide information to SAM about certain civil, criminal, and administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil, and administrative proceedings as specified in the applicable Representations (see General Application Instructions, Appendix 8, Section B).

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | [Post-Award Requirements](#) | Other Information

### 8.3. Additional Requirements

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

An organizational transfer of an award will not be allowed in the last year of the (original) period of performance or any extension thereof.

Refer to the General Application Instructions, Appendix 7, Section H, for general information on organization or PI changes.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

# 9. Other Information

## 9.1. Program Announcement and General Application Instructions Versions

Questions related to this program announcement should refer to the program name, the program announcement name, and the program announcement version code CD25\_01d. The program announcement numeric version code will match the General Application Instructions version code CD25\_01.

## 9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

### 9.2.1. Rejection

The following will result in administrative rejection of the full application:

- Pre-application was not submitted.
- Project Narrative is missing.
- Budget is missing.

### 9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to review for all documents.
- Documents not requested will be removed.

### 9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY25 BCRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- Applications that include names of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY25, the identities of the peer review contractor and the programmatic review contractor may be found on the [CDMRP website](#).
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- Applications from extramural organizations, including non-DOD federal agencies, received through eBRAP.
- Applications submitted by a federal government organization (including an intramural DOD organization) if: (a) the organization cannot accept and execute the entirety of the requested budget in FY25 funds; and/or (b) the federal government organization cannot coordinate the use of contractual, assistance, or other appropriate agreements to provide funds to collaborators.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | [Other Information](#)

- The application fails to conform to this program announcement description.
- Inclusion of URLs, with the exception of links in References Cited and Publication and/or Patent Abstract sections.
- Application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- Submission of the same research project to different funding opportunities within the same program and funding cycle.
- The application does not address at least one of the [FY25 BCRP Overarching Challenges](#) and did not provide adequate justification for exception.
- The PI does not meet the eligibility criteria.
- A clinical trial is proposed.
- Application fails to include two consumer advocates on the research team as required by this program announcement.
- **Partnering PI Option:** Failure to submit all associated (Initiating and Partnering PI) applications by the deadline.

### 9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the USAMRAA Grants Officer for a determination of the final disposition of the application.

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

## Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded	
	PI/Initiating PI	Partnering PI
SF424 Research & Related Application for Federal Assistance <i>(Grants.gov submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
Summary (Tab 1) and Application Contacts (Tab 2) <i>(eBRAP submissions only)</i>	<input type="checkbox"/>	<input type="checkbox"/>
<b>Attachments</b>		
<a href="#">Project Narrative</a> – Attachment 1, upload as “ProjectNarrative.pdf”	<input type="checkbox"/>	
<a href="#">Supporting Documentation</a> – Attachment 2, upload as “Support.pdf”	<input type="checkbox"/>	
<a href="#">Technical Abstract</a> – Attachment 3, upload as “TechAbs.pdf”	<input type="checkbox"/>	
<a href="#">Lay Abstract</a> – Attachment 4, upload as “LayAbs.pdf”	<input type="checkbox"/>	
<a href="#">Statement of Work</a> – Attachment 5, upload as “SOW.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
<a href="#">Impact Statement</a> – Attachment 6, upload as “Impact.pdf”	<input type="checkbox"/>	
<a href="#">Partnership Statement</a> <i>(if applicable)</i> – Attachment 7, upload as “Partnership.pdf”	<input type="checkbox"/>	
<a href="#">Research Team Statement</a> – Attachment 8, upload as “Team.pdf”	<input type="checkbox"/>	
<a href="#">Inclusion of Women and Minorities</a> – Attachment 9, upload as “Inclusion.pdf”	<input type="checkbox"/>	
<a href="#">Data and Research Resources Sharing Plan</a> – Attachment 10, upload as “Sharing.pdf”	<input type="checkbox"/>	
<a href="#">Representations</a> <i>(Grants.gov submissions only)</i> – Attachment 11, upload as “RequiredReps.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
<a href="#">Suggested Intragovernmental/Intramural Budget Form</a> <i>(if applicable)</i> – Attachment 12, upload as “IGBudget.pdf”	<input type="checkbox"/>	<input type="checkbox"/>
Research & Related Personal Data	<input type="checkbox"/>	<input type="checkbox"/>
Research & Related Senior/Key Person Profile (Expanded)	<input type="checkbox"/>	<input type="checkbox"/>
Attach <a href="#">Biographical Sketch</a> for PI and Senior/Key Persons (Biosketch_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
Attach <a href="#">Current and Pending (Other) Support</a> for PI and Senior/Key Persons (Support_LastName.pdf)	<input type="checkbox"/>	<input type="checkbox"/>
Budget Include budget justification	<input type="checkbox"/>	<input type="checkbox"/>
Project/Performance Site Location(s) Form	<input type="checkbox"/>	<input type="checkbox"/>
Research & Related Subaward Budget Attachment(s) Form <i>(if applicable)</i>	<input type="checkbox"/>	<input type="checkbox"/>

## Section Shortcuts

Basic Information | Eligibility | Program Description | Application Contents and Format | Submission Requirements  
Application Review Information | Federal Award Notices | Post-Award Requirements | Other Information

## Appendix 2. Acronym List

BCRP	Breast Cancer Research Program
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CREA	Clinical Research Extension Award
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
IACUC	Institutional Animal Care and Use Committee
IRB	Institutional Review Board
LOI	Letter of Intent
M	Million
MIPR	Military Interdepartmental Purchase Request
NCT	National Clinical Trial
NIH	National Institutes of Health
NSF	U.S. National Science Foundation
OHRO	Office of Human Research Oversight (previously Human Research Protection Office)
OUSD R&E	Office of the Under Secretary of Defense, Research and Engineering
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
PPIO	Partnering PI Option
RPPR	Research Performance Process Report
SAM	System for Award Management
SciENCv	Science Experts Network Curriculum Vitae
SOW	Statement of Work
URL	Uniform Resource Locator
USAMRAA	U.S. Army Medical Research Acquisition Activity
USAMRDC	U.S. Army Medical Research and Development Command
USC	United States Code
VA	U.S. Department of Veteran Affairs